publication . Preprint . 2019

VGF in cerebrospinal fluid, when combined with conventional biomarkers, enhances prediction of conversion from mild cognitive impairment to Alzheimer’s Disease

Llano, Daniel A.; Devanarayan, Priya; Devanarayan, Viswanath;
Open Access English
  • Published: 07 Jan 2019
  • Publisher: Cold Spring Harbor Laboratory
Abstract
Abstract Sensitive and accurate biomarkers for the prediction of conversion from mild cognitive impairment (MCI) to Alzheimer’s Disease (AD) are needed to both support clinical care and enhance clinical trial design. Here, we examined the potential of cerebrospinal fluid (CSF) levels of a peptide derived from a neural protein involved in synaptic transmission, VGF (a non-initialism), to enhance accuracy of prediction of conversion from MCI to AD. The performance of conventional biomarkers (CSF Aβ1-42 and phosphorylated tau +/− hippocampal volume) was compared to the same biomarkers with CSF VGF peptide levels. It was observed that VGF peptides are lowered in pat...
Funded by
CIHR
Project
  • Funder: Canadian Institutes of Health Research (CIHR)
,
NIH| Alzheimers Disease Neuroimaging Initiative
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
  • Funding stream: NATIONAL INSTITUTE ON AGING
Download from
18 references, page 1 of 2

Dubois, B., et al., Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimer's & Dementia, 2016. 12(3): p. 292-323.

Bloom, G.S., Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA neurology, 2014. 71(4): p. 505-508.

Haass, C. and D.J. Selkoe, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nature reviews Molecular cell biology, 2007. 8(2): p. [OpenAIRE]

Sengupta, U., A.N. Nilson, and R. Kayed, The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy. EBioMedicine, 2016. 6: p. 42-49. [OpenAIRE]

Nature Reviews Neurology, 2010. 6(3): p. 131.

Perrin, R.J., A.M. Fagan, and D.M. Holtzman, Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature, 2009. 461(7266): p. 916.

Dubois, B., et al., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. The Lancet Neurology, 2007. 6(8): p. 734-746.

Rasmusson, D., et al., Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer disease and associated disorders, 1996. 10(4): p. 180-188. [OpenAIRE]

Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2013. 9(4): p.

P845-P846.

Beach, T.G., et al., Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. Journal of neuropathology and experimental neurology, 2012. 71(4): p. 266-273.

Qian, W., et al., Misdiagnosis of Alzheimer's disease: Inconsistencies between clinical diagnosis and neuropathological confirmation. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016. 12(7): p. P293.

Yu, P., et al., Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. Journal of Alzheimer's disease, 2012. 32(2): p. 373-385.

van Rossum, I.A., et al., Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. Journal of Alzheimer's Disease, 2010. 20(3): p. 881-891.

Westin, K., et al., CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PloS one, 2012. 7(1): p. e30525.

18 references, page 1 of 2
Abstract
Abstract Sensitive and accurate biomarkers for the prediction of conversion from mild cognitive impairment (MCI) to Alzheimer’s Disease (AD) are needed to both support clinical care and enhance clinical trial design. Here, we examined the potential of cerebrospinal fluid (CSF) levels of a peptide derived from a neural protein involved in synaptic transmission, VGF (a non-initialism), to enhance accuracy of prediction of conversion from MCI to AD. The performance of conventional biomarkers (CSF Aβ1-42 and phosphorylated tau +/− hippocampal volume) was compared to the same biomarkers with CSF VGF peptide levels. It was observed that VGF peptides are lowered in pat...
Funded by
CIHR
Project
  • Funder: Canadian Institutes of Health Research (CIHR)
,
NIH| Alzheimers Disease Neuroimaging Initiative
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
  • Funding stream: NATIONAL INSTITUTE ON AGING
Download from
18 references, page 1 of 2

Dubois, B., et al., Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimer's & Dementia, 2016. 12(3): p. 292-323.

Bloom, G.S., Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA neurology, 2014. 71(4): p. 505-508.

Haass, C. and D.J. Selkoe, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nature reviews Molecular cell biology, 2007. 8(2): p. [OpenAIRE]

Sengupta, U., A.N. Nilson, and R. Kayed, The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy. EBioMedicine, 2016. 6: p. 42-49. [OpenAIRE]

Nature Reviews Neurology, 2010. 6(3): p. 131.

Perrin, R.J., A.M. Fagan, and D.M. Holtzman, Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature, 2009. 461(7266): p. 916.

Dubois, B., et al., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. The Lancet Neurology, 2007. 6(8): p. 734-746.

Rasmusson, D., et al., Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer disease and associated disorders, 1996. 10(4): p. 180-188. [OpenAIRE]

Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2013. 9(4): p.

P845-P846.

Beach, T.G., et al., Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. Journal of neuropathology and experimental neurology, 2012. 71(4): p. 266-273.

Qian, W., et al., Misdiagnosis of Alzheimer's disease: Inconsistencies between clinical diagnosis and neuropathological confirmation. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016. 12(7): p. P293.

Yu, P., et al., Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. Journal of Alzheimer's disease, 2012. 32(2): p. 373-385.

van Rossum, I.A., et al., Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. Journal of Alzheimer's Disease, 2010. 20(3): p. 881-891.

Westin, K., et al., CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PloS one, 2012. 7(1): p. e30525.

18 references, page 1 of 2
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue